GLUEMonte Rosa Therapeutics, Inc.

1. Oct 1, 2026On October 1, 2026, the Company announced positive data from GFORCE-1, a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of NLRP3/IL-1-driven inflammatory diseases.Regulation FD disclosure · Form 8-K
2. Sep 8, 2026As previously disclosed, the Company is party to a global exclusive development and commercialization license agreement (the “Novartis Agreement”) with Novartis pursuant to which Novartis has exclusive worldwide rights to develop, manufacture and commercialize VAV1-directed MGDs, including MRT-6160 (DDY391)Regulation FD disclosure · Form 8-K
3. Aug 6, 2026Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates.Earnings release · press release
4. May 7, 2026Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates.Earnings release · press release
5. Feb 10, 2026On January 9, 2026, Edmund Dunn informed us of his intent to retire from the role of SVP, Corporate Controller and Principal Accounting Officer of Monte Rosa Therapeutics, Inc. (the “Company”), effective as of April 3, 2026.Director or officer change · Form 8-K
6. Jan 9, 2026On January 8, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC, TD Securities (USA) LLC and Piper Sandler & Co., as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”) …Material agreement entered · Form 8-K
7. Jan 7, 2026Effective January 7, 2026, Monte Rosa Therapeutics, Inc. (the “Company”) terminated the sales agreement prospectus (the “ATM Prospectus”) filed with the Company’s registration statement on Form S-3 (File No. 333-285942) (the “Registration Statement”) and related to the shares of the Company’s common stock, par value …Other event · Form 8-K
8. Jan 7, 2026On January 7, 2026, the Company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102, a NEK7-directed MGD being developed for the treatment of inflammatory conditions driven by the NLRP3 inflammasome, IL-1, and IL-6.Regulation FD disclosure · Form 8-K
9. Dec 16, 2025On December 16, 2025, the Company announced positive interim data from its ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic CRPC. The Phase 1/2 study evaluated 0.5 mg and 0.75 mg of MRT-2359 administered orally on a 21-days-on …Regulation FD disclosure · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.